Trial reportAddiction (Abingdon, England)2013
Aripiprazole for the treatment of methamphetamine dependence: a randomized, double-blind, placebo-controlled trial.
Trial report in Addiction (Abingdon, England), 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 31 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Aripiprazole Treatment for Methamphetamine Dependence Among High-risk Individuals
Better Than Study: Targeting Heavy Alcohol Use With Naltrexone Among MSM
Who cites it
31 citing papers in PubMed, 3 syntheses or guidelines pooled it, 65 citations in OpenAlex.
- Translational medications development for methamphetamine use disorder: A systematic review of preclinical, human laboratory, and clinical research.Pharmacological reviews · 2026Pooled it
- Evidence-based consensus guidelines for the pharmacological management of substance dependence: Recommendations from the British Association for Psychopharmacology.Journal of psychopharmacology (Oxford, England) · 2026Guideline
- Pharmacological Treatment of Methamphetamine/Amphetamine Dependence: A Systematic Review.CNS drugs · 2020Pooled it
- Ifenprodil for the treatment of methamphetamine use disorder: An exploratory, randomized, double-blind, placebo-controlled trial.Neuropsychopharmacology reports · 2022Trial
- Randomized controlled trial of a positive affect intervention for methamphetamine users.Drug and alcohol dependence · 2018Trial
- Correlates of Validity of Self-Reported Methamphetamine Use among a Sample of Dependent Adults.Substance use & misuse · 2018Trial
- Extended-release naltrexone for methamphetamine dependence among men who have sex with men: a randomized placebo-controlled trial.Addiction (Abingdon, England) · 2018Trial
- Trial
- Sustained-release methylphenidate in methamphetamine dependence treatment: a double-blind and placebo-controlled trial.Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 2015Trial
- Event-level relationship between methamphetamine use significantly associated with non-adherence to pharmacologic trial medications in event-level analyses.Drug and alcohol dependence · 2014Trial
- Sustained-release methylphenidate in a randomized trial of treatment of methamphetamine use disorder.Addiction (Abingdon, England) · 2014Trial
- Aripiprazole effects on self-administration and pharmacodynamics of intravenous cocaine and cigarette smoking in humans.Experimental and clinical psychopharmacology · 2014Trial
- Artificial intelligence-based drug repurposing with electronic health record clinical corroboration: A case for ketamine as a potential treatment for amphetamine-type stimulant use disorder.Addiction (Abingdon, England) · 2025Article
- Therapeutic targeting of neuroinflammation in methamphetamine use disorder.Future medicinal chemistry · 2025Review
- Pharmacological Treatments for Methamphetamine Use Disorder: Current Status and Future Targets.Substance abuse and rehabilitation · 2024Review
- Psychosocial and pharmacologic interventions for problematic methamphetamine use: Findings from a scoping review of the literature.PloS one · 2023Article
- A mechanistic overview of approaches for the treatment of psychostimulant dependence.Frontiers in pharmacology · 2022Review
- Psychosocial and pharmacologic interventions for methamphetamine addiction: protocol for a scoping review of the literature.Systematic reviews · 2020Article
- Study of effects of ifenprodil in patients with methamphetamine dependence: Protocol for an exploratory, randomized, double-blind, placebo-controlled trial.Neuropsychopharmacology reports · 2019Article
- Paliperidone Extended-Release Tablets for the Treatment of Methamphetamine Use Disorder in Chinese Patients After Acute Treatment: A Randomized, Double-Blind, Placebo-Controlled Exploratory Study.Frontiers in psychiatry · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
Abstract
aimsTo test aripiprazole for efficacy in decreasing use in methamphetamine-dependent adults, compared to placebo.
designParticipants were randomized to receive 12 weeks of aripiprazole or placebo, with a 3-month follow-up and a platform of weekly 30-minute substance abuse counseling.
settingThe trial was conducted from January 2009 to March 2012 at the San Francisco Department of Public Health.
participantsNinety actively using, methamphetamine-dependent, sexually active adults were recruited from community venues. MEASUREMENTS: The primary outcome was regression estimated reductions in weekly methamphetamine-positive urines. Secondary outcomes were study medication adherence [by self-report and medication event monitoring systems (MEMS)], sexual risk behavior and abstinence from methamphetamine.
findingsParticipant mean age was 38.7 years, 87.8% were male, 50.0% white, 18.9% African American, and 16.7% Latino. Eighty-three per cent of follow-up visits and final visits were completed. By intent-to-treat, participants assigned to aripiprazole had similar reductions in methamphetamine-positive urines as participants assigned to placebo [risk ratio (RR) 0.88, 95% confidence interval (CI): 0.66-1.19, P = 0.41]. Urine positivity declined from 73% (33 of 45 participants) to 45% (18 of 40) in the placebo arm and from 77% (34 of 44) to 44% (20 of 35) in the aripiprazole arm. Adherence by MEMS and self-report was 42 and 74%, respectively, with no significant difference between arms (MEMS P = 0.31; self-report P = 0.17). Most sexual risk behaviors declined similarly among participants in both arms (all P > 0.05). There were no serious adverse events related to study drug, although participants randomized to aripiprazole reported more akathisia, fatigue and drowsiness (P < 0.05).
conclusionCompared with placebo, aripiprazole did not reduce methamphetamine use significantly among actively using, dependent adults.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.